

AIM ImmunoTech Inc.

generates minimal revenue.

Q3 about inline. Wins proxy battle. Clinical data expected to be strong catalysts for stock over the next year. Lowering P/T to \$6.75.

COMPANY UPDATE

Rating: BUY

Ticker:	AIM
Price:	\$0.44
Target:	\$6.75
(fro	om \$7.25)

Q3 about inline: AIM recently (on November 15) reported its Q3 2022 (ending September) results. Net loss was \$6.4 million or EPS of (0.13), compared with our and consensus estimates of (0.09) - (0.10). There was no guidance. AIM is an early/clinical stage drug development/commercialization company so it

Q3 update: Operating expenses were \$6.5 million, vs. \$4.7 million in Q2 2022 as the company spent \$3 million in legal fees for its proxy battle.

No guidance: Management did not provide forward guidance but we believe ~\$4 million is a reasonable near term quarterly cash burn rate.

Adjusting estimates: We are adjusting our 2022 EPS estimate to \$(0.43) from \$(0.40).

Ramp up in clinical trials: In October, the company announced that the FDA has allowed it to proceed to initiate a Phase 2 study evaluating Ampligen as a therapeutic for patients with post-COVID conditions. This study is expected to start in Q1 2023. A major Phase 2 study for Ampligen for pancreatic cancer started in Q3 2022 (in August). Also in August, the company announced that its clinical development collaborator, Roswell Park Comprehensive Cancer Center, in a clinical trial fully funded by the National Cancer Institute (NCI), has commenced patient enrollment in its Phase 2 study in subjects to test Ampligen in patients with primary PD-1/PD-L1 resistant melanoma.

Positive data from 2 studies: In April, AIM announced positive data from a Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM's drug candidate, Ampligen. Also in April, AIM announced positive data from a Phase 2a study (also at Roswell Park) evaluating Ampligen as a component of a chemokine modulatory (CKM) regimen for the treatment of colorectal cancer metastatic to the live.

Multiple shots on goal: In collaboration with major cancer research centers in the U.S., clinical trials are underway to test that the combination of Ampligen with checkpoint blockade therapies will improve clinical tumor responses, time to progression, and survival rates. There are nine cancer clinical trials underway or planned at including the University of Pittsburgh Medical Center, Roswell Park Comprehensive Cancer Center, and University of Nebraska Medical Center.

Clinical data can be catalyst: AIM anticipates receiving additional clinical data from its various trials over the next year. Initial and recent data has been positive and further strong positive data will likely be catalysts for the stock.

Wins proxy battle: In November, the company's 3 nominee to the Board were all reelected rebuffing a proxy battle with AS Full Value Committee.

Solid balance sheet: In Q3, the company has \$37 million in cash and no debt. We believe the company has enough cash into 2024.

Positive high risks versus rewards: We acknowledge that AIM's oncology drugs still have long development roads left (~3 years), but we believe the ~billion dollars market potentials presents a high reward for the risks.

Current valuation attractive: We are maintaining our BUY rating, but lowering our 12-month price target to \$6.75 from \$7.25, which is based on a NPV analysis. We believe this valuation appropriately balances out the company's high risks with its high growth prospects and large upside opportunities.

Company Description

Based in Ocala, FL, AIM ImmunoTech is a biotech company engaged in the clinical development of new drug therapies for the treatment of viral, immune, and immuno-oncology based diseases.

United States Healthcare

November 23, 2022

Edward Woo, CFA (561) 327-9435 ewoo@ascendiant.com

Stock Data

Exchange:	NYSE
52-week Range:	\$0.42 - 1.51
Shares Outstanding (million):	48
Market cap (\$million):	\$21
EV (\$million):	\$(16)
Debt (\$million):	\$0
Cash (\$million):	\$37
Avg. Daily Trading Vol. (\$million):	\$0.2
Float (million shares):	47
Short Interest (million shares):	1
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2022E</u> (Cur.)	<u>2022E</u> (Old)	<u>2023E</u> (Cur.)	<u>2023E</u> (Old)
Q1 Mar	0.0A		0.0E	
Q2 Jun	0.0A		0.0E	
Q3 Sep	0.0A	0.0E	0.0E	
Q4 Dec	<u>0.1E</u>		<u>0.1E</u>	
Total	0.1E	0.2E	0.2E	
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	<u>2022E</u>	<u>2022E</u>	<u>2023E</u>	<u>2023E</u>
	<u>(Cur.)</u>	<u>(Old)</u>	<u>(Cur.)</u>	<u>(Old)</u>
Q1 Mar	(0.08)A		(0.11)E	
Q2 Jun	(0.10)A		(0.11)E	
Q3 Sep	(0.13)A	(0.10)E	(0.11)E	
Q4 Dec	<u>(0.12)E</u>		<u>(0.11)E</u>	
Total	(0.43)E	(0.40)E	(0.43)E	
P/E	N/A		N/A	

Important Disclosures

Ascendiant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 13.



Exhibit 1: AIM ImmunoTech's Overview

Investor Highlights

We are an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders

Lead program Ampligen[®] is an immuno-modulator with broad spectrum activity potentially applicable in multiple high-value indications

Multiple oncology clinical programs with upcoming clinical and regulatory milestones Antiviral studies, including COVID-19, either underway or in development Only late-stage program in development in the U.S. for the treatment of ME/CFS, with an approval in Argentina for severe CFS

Investment Summary

Immuno-Pharma Company with Broad Pipeline Across Multiple High-Value Indications in Oncology, Virology and Immune-Deficiency

Lead program Ampligen® has favorable safety profile and promising efficacy Leveraging external collaborators to fund ongoing clinical studies Growing body of data potentially supports development strategy

Strong Balance Sheet

Multiple Potentially Game-Changing Clinical and Regulatory Milestones Both Achieved and Expected Throughout 2022



Exhibit 2: Company Development Pipeline

Broad Oncology Pipeline Across High-Value Indications

Indications	Approach	Partner	Preclinical Phase 1 Phase 2 Phase 3 Approval
Ovarian Cancer (Advanced, Recurrent)	Chemokine Modulatory Regimen		
Colorectal Cancer (Metastatic)	Chemokine Modulatory Regimen	ROSWELL PARK.	
Breast Cancer (Metastatic Triple-Negative)	Chemokine Modulatory Regimen / Pembrolizumab	ROSWELL PARK.	
Ovarian Cancer (Advanced, Recurrent)	Combination: Pembrolizumab		
Prostate Cancer (Early-Stage)	Combination: Intron A	ROSWELL PARK.	
Pancreatic Cancer	Single Agent	Erasmus MC Caluy	Early Access Program
Pancreatic Cancer (Locally Advanced)	Ampligen following FOLFIRINOX		
Breast Cancer (Early-Stage Triple- Negative)	Chemokine Modulatory Plus Neoadjuvant Chemo	ROSWELL	
Pancreatic Cancer	Ampligen Plus Checkpoint Inhibitor	University of Nebraska Medical Center: BEAKTHROUGHS FOR LIFE	
Melanoma	Single Agent		
Melanoma (Refractory)	Combination Tumor-Selective Chemokine Modulation	ROSWELL. PARK.	

Extensive Viral and Immune System Disorder Pipeline

Indications	Approach	Preclinical	Phase 1	Phase 2	Phase 3	Approval
Viral Infections						
COVID-19 in Cancer Patients	Combination: Interferon Alpha-2b and Ampligen®					
Immune System Disorder						
Severe CFS	Single Agent					<u>Approved in</u> <u>Argentina</u>
ME/CFS	Single Agent				anning Phase 3 nfirmatory Trial	
Post-COVID Conditions	Single Agent	IND Planning Underway			s in FDA Authorize te Care Program	d



Exhibit 3: Ampligen Market Opportunity

Lead Program Ampligen[®] (rintatolimod) Significant Opportunity Across Multiple Disease Areas

Generally well-tolerated with over 100,000 IV doses in humans

Clinically tested in oncology as a single-agent therapeutic and in combination with other agents

Potential in oncology to enhance efficacy of PD-1 and PD-L1 checkpoint inhibitors ^1 $\,$

Phase 3 in ME/CFS completed in U.S. – NDA filing pending confirmatory Phase 3 following complete response letter; Approved for the treatment of severe CFS in Argentina Immuno-Oncology

Virology

Immune System Disorders

Ampligen[®] May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19)

Targeting toll-like receptor 3 (TLR3) pathways, which are among the primary pathways for antiviral protection (uniquely targets TLR3 without activation of the inflammatory cytosolic helicases)

Potential efficacy may not be impacted by viral mutations, such as Delta, Omicron or future given mechanism of action

Demonstrated complete protection (100% survival) against SARS-CoV-1, Ebola virus disease, and Western Equine Encephalitis virus in preclinical studies

Identified an effective *in vitro* model using human tracheal, bronchial epithelial cells, which showed that Ampligen® was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen® dosage levels

Ampligen[®] for the Treatment of ME/CFS

Only late-stage program in development in the U.S. for the treatment of ME/CFS, with an approval in Argentina



Developing protocol for confirmatory Phase 3 trial, required for U.S. NDA

Toll-Like Receptor 3 agonist which activates the innate immune system and induces immuno-modulation



Exhibit 4: Ongoing Ampligen Cancer Clinical Studies (as of November 15, 2022)

Immuno-Therapy Targeting Multiple Cancers with High Unmet Need

- Locally Advanced Pancreatic Cancer ("LAPC") The Company recently commenced its Phase 2 study of Ampligen as a therapy for LAPC (AMP-270) following receipt of Institutional Review Board ("IRB") approval for the trial protocol. The AMP-270 clinical trial is a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Secondary objectives include comparing safety and tolerability. AMP-270 is expected to enroll approximately 90 subjects in up to 30 centers across the United States and Europe. The Buffett Cancer Center at the University of Nebraska Medical Center and Erasmus MC in the Netherlands are expected to be the primary study sites. ClinicalTrials.gov: NCT05494697.
- Advanced Recurrent Ovarian Cancer Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer. Phase 1 portion was completed and published in the American Association for Cancer Research publication, Clinical Cancer Research (Clin Cancer Res January 19, 2022 DOI: 10.1158/1078-0432.CCR-21-3659). The Phase 2 portion of the study is planned to be conducted in the future. ClinicalTrials.gov: NCT02432378
- Advanced Recurrent Ovarian Cancer A follow-up Phase 2 study of advanced recurrent ovarian cancer using cisplatin and pembrolizumab, plus
 Ampliger; up to 45 patients to be enrolled; numerous patients have commenced treatment. We announced interim data from the study demonstrating
 that evidence of increased biomarkers associated with T cell chemotaxis and cytolytic function was seen when combining Ampligen, pembrolizumab
 and cisplatin. Increases of these biomarkers in the tumor microenvironment have been correlated with favorable tumor responses. Interim results
 announced March 2022 detailed an observed clinical response rate of 61% includes two complete and three partial tumor responses, plus three
 patients with stable disease among the 13 evaluable patients. An important priority will be to confirm these findings through continuing to enroll
 patients onto this study. ClinicalTrials.gov: NCT03734692
- Stage 4 Colorectal Cancer Metastatic to the Liver Phase 2a study of Ampligen as a component of a chemokine modulatory regimen on colorectal
 cancer metastatic to liver was completed and met primary endpoint, evidenced by increased CD8a expression post-treatment (p=0.046).; 15 patients
 were treated and 12 patients were evaluable for the primary endpoint. Data suggest that chemokine modulatory (CKM) regimen with Ampligen may be
 useful to enhance effectiveness of immunotherapies. The data from the Phase 2a study was presented in April 2022 at the American Association for
 Cancer Research (AACR) Annual Meeting 2022. ClinicalTrials.gov: NCT03403634
- Stage 4 Metastatic Triple Negative Breast Cancer Phase 1 study of metastatic triple-negative breast cancer using CKM therapy, including Ampligen
 and pembrolizumab, successfully met primary endpoint. Positive data from this proof-of-concept study demonstrate that short-term systemic CKM
 followed by pembrolizumab is well-tolerated and selectively enhances local cytotoxic T-lymphocyte (CTL) infiltration in the tumor microenvironment
 (TME). The data from the Phase 1 study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in April 2022.
 ClinicalTrials.gov: NCT03599453
- Early-Stage Prostate Cancer Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy. Patient enrollment has been initiated in this study designed for up to 45 patients. ClinicalTrials.gov: NCT03899987
- Early-Stage Triple Negative Breast Cancer Phase 1 study of chemokine modulation plus neoadjuvant chemotherapy in patients with early-stage triple negative breast cancer has received FDA authorization. The objective of this study is to evaluate the safety and tolerability of a combination of Ampligen and celecoxib with or without Intron A, when given along with chemotherapy. The goal of this approach is to increase survival. Positive data was recently presented at the SITC 37th Annual Meeting demonstrating the Chemokine-Modulating (CKM) Regimen including Ampligen was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic). Planning is underway for a Phase 2 study in early-stage TNBC to determine if CKM including Ampligen may be a safe and effective alternative to pembrolizumab or pembrolizumab/neoadjuvant chemotherapy. ClinicalTrials.gov: NCT04081389
- Refractory Melanoma Phase 2 study that will evaluate polarized dendritic cell vaccine, interferon alpha-2, Ampligen and celecoxib for the treatment
 of HLA-A2+ refractory melanoma at Roswell Park. Up to 24 patients to be enrolled. ClinicalTrials.gov: NCT04093323
- Advanced Ovarian Cancer AIM plans to develop a Phase 2 Cisplatin Resistant Advanced Recurrent Ovarian Cancer Clinical Study utilizing Ampligen at the University of Pittsburgh.



Exhibit 5: Ampligen for COVID-19 and ME/CFS (as of November 15, 2022)

Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19)

Previous animal studies yielded positive results utilizing Ampligen in Western Equine Encephalitis Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1. The Company has conducted experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication. The prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against SARS-CoV-2. AIM is currently evaluating the safety and effectiveness of intravenous Ampligen to reduce replication of SARS-CoV-2 virus from upper airway in patients in an ongoing Phase 1/2 study for the treatment of COVID-19 cancer patients. The Company plans to conduct an intranasal study of Ampligen to potentially enhance and expand natural immunity.

The FDA has authorized Ampligen in a clinical trial of patients with COVID-19 who have a pre-existing cancer. That Phase 1/2a study utilizing Ampligen is underway in the investigator-sponsored Phase 2 trial at the Roswell Park Comprehensive Cancer Center. ClinicalTrials.gov: NCT04379518

Immune System Disorders (ISD): Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) / COVID-19 Long Hauler

The Company is currently sponsoring an ongoing, FDA-authorized AMP-511 (See: ClinicalTrials.gov: NCT00215813) expanded access program (EAP) for ME/CFS patients in the United States. AIM has enrolled five post-COVID patients with new onset ME/CFS following acute COVID-19. Preliminary results based on data from the first 4 patients, following at least 12 weeks of Ampligen treatment indicated they had experienced a reduction in fatigue, as measured via Patient-Reported Outcomes questionnaires. A statistical analysis of these data indicated that the decrease in fatigue compared to baseline was statistically significant (p<0.002), despite the small number of patients. Based in part on these early positive data, the FDA recently provided their clearance of the Company's IND application for a Phase 2 study of Ampligen for the treatment of Post-COVID Conditions.

Ongoing Phase 1/2 Study for Treatment of COVID-19 Cancer Patients

Actively Enrolling and Dosing Subjects

Evaluating safety and effectiveness of intravenous Ampligen® to reduce replication of SARS-CoV-2 virus from upper airway in patients

Next Steps: Planning intranasal study of Ampligen[®] to potentially enhance and expand natural immunity



Exhibit 6: AIM Upcoming Milestones (as of October 2022)

2022 Milestones

Q1 2022

Q2 2022

Q3 2022

Oncology

- ✓ January 2022: Advanced Recurrent Ovarian Cancer: Phase 1 Publication of Results
- ✓ March: Late-Stage Pancreatic Cancer: EAP Publications of Results
- ✓ March 2022: Advanced Recurrent Ovarian Cancer: Phase 2 Interim Results
- ✓ March 2022: FDA IND clearance of Phase 2 Locally advanced Pancreatic Cancer study

Oncology

- ✓ Pancreatic Cancer Expressing TLR3 Receptors: Publication of Preclinical Data
- ✓ Metastatic Triple-Negative Breast Cancer: Phase 1/2 Results
- ✓ Colorectal Cancer Metastatic to Liver: Phase 2a Results

Immune System Disorders

✓ Report Interim Results from AMP-511 COVID-19 and Progress from Planned Post-COVID Phase 2

Oncology

- ✓ Locally Advanced Pancreatic Cancer: Launch Phase 2 Study
- ✓ HLA-A2+ Melanoma: Recruiting

Antiviral

 COVID-19 in Cancer Patients: Phase 1/2 Interim Results



Exhibit 7: Q3 2022 and Recent Highlights (as of November 15, 2022)

- Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones

- Cash position expected to fund operations through end of 2023

Recent Highlights

- Presented positive data from research led by Roswell Park Comprehensive Cancer Center medical oncologist, Shipra Gandhi, MD, evaluating Ampligen[®] (rintatolimod) as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer (TNBC) at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
- Received Orphan Drug Designation for Ampligen[®] (rintatolimod) for the treatment of Ebola Virus Disease.
- Announced FDA clearance of IND application to evaluate Ampligen in Phase 2 clinical study for the treatment of post-COVID conditions.
- Commenced enrollment with study collaborator, Roswell Park, in an NCI-funded Phase 2 clinical trial evaluating Ampligen in primary PD-1/PD-L1
 Resistant Melanoma.
- Announced commencement of Phase 2 study of Ampligen for the treatment of Pancreatic Cancer.

AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

ONovember 3, 2022 · 3 min read





Source: https://bigcharts.marketwatch.com/

Exhibit 9: Con	sensus Expectations	s (as of November 15	i, 2022)		
	Revenue (mil)			EPS	
	<u>2022E</u>	<u>2023E</u>		<u>2022E</u>	<u>2023E</u>
Q1 Mar	\$0.0A		Q1 Mar	\$(0.08)A	
Q2 Jun	\$0.0A		Q2 Jun	\$(0.10)A	
Q3 Sep	\$0.2E		Q3 Sep	\$(0.09)E	
Q4 Dec	\$0.2E		Q4 Dec	\$(0.10)E	
Total	\$0.4E	\$1.0E	Total	\$(0.35)E	\$(0.39)E

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

Source: Company report, Refinitiv, and Ascendiant Capital Markets estimates



FINANCIAL MODEL

AIM ImmunoTech Inc.

Income Statement (\$ mils)	Mar-20	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.2
Total Revenue	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.2
Cost of Revenues	0.2	0.2	0.2	0.2	0.8	0.2	0.3	0.2	0.2	0.9	0.1	0.1	0.0	0.1	0.3	0.1	0.1	0.1	0.1	0.3
Gross Profit	(0.2)	(0.2)	(0.2)	(0.2)	(0.6)	(0.2)	(0.3)	(0.1)	(0.1)	(0.7)	(0.0)	(0.0)	0.0	(0.1)	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.2
Research and development	0.9	1.5	1.1	2.3	5.7	1.4	1.3	2.0	2.9	7.7	1.0	2.5	1.4	3.5	8.4	3.0	3.0	3.0	3.0	12.0
General and administrative	2.3	1.7	2.1	2.6	8.7	2.1	2.1	1.8	2.6	8.7	2.1	2.2	5.2	2.0	11.4	2.2	2.2	2.2	2.2	8.8
Restructuring and other	-			0.1	0.1				1.8	1.8					0.0					0.0
Total operating expenses	3.2	3.2	3.2	5.0	14.5	3.5	3.5	3.8	7.3	18.1	3.1	4.7	6.5	5.5	19.8	5.2	5.2	5.2	5.2	20.8
Operating income (loss)	(3.3)	(3.3)	(3.4)	(5.1)	(15.2)	(3.7)	(3.7)	(3.9)	(7.4)	(18.8)	(3.2)	(4.7)	(6.5)	(5.6)	(19.9)	(5.2)	(5.2)	(5.2)	(5.3)	(21.0)
								()	<i>(</i> -)											
Interest income (expense)	(0.3)	(0.2)	0.0	0.0	(0.5)	0.0	0.0	(0.0)	(0.1)	(0.1)	0.0	0.1	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0
Other income (expense) Income before income taxes	(0.2) (2.0)	0.2	<u>0.0</u> (3.3)	<u>1.2</u> (3.9)	<u>1.2</u>	0.1	(2.2)	0.1	<u>1.7</u>	(0.2)	(0.7)	(0.2)	(0.0)	(5.0)	(<u>1.0</u>)	(5.0)	(5.0)	(5.0)	(5.0)	0.0
Income berore income taxes	(3.8)	(3.4)	(3.3)	(3.9)	(14.4) 0.0	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(3.8)	(4.9)	(6.4)	<mark>(5.6)</mark> 0.0	(20.6) 0.0	(5.2)	(5.2)	(5.2)	(5.3)	(21.0
Net income (loss)	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	<u>0.0</u> (19.1)	(3.8)	(4.9)	(6,4)	(5.6)	(20.6)	<u>0.0</u> (5.2)	<u>0.0</u> (5.2)	<u>0.0</u> (5.2)	<u>0.0</u> (5.3)	<u>0.0</u> (21.0
Net income (1035)	(3.0)	(3.4)	(3.3)	(3.3)	(14.4)	(3.0)	(3.3)	(3.0)	(3.0)	(13.1)	(3.0)	(4.3)	(0.4)	(3.0)	(20.0)	(3.2)	(3.2)	(3.2)	(3.3)	(21.0
Nonrecurring/noncash adjustme					<u>0.0</u>					<u>0.0</u>					0.0					0.0
Net income (pro forma)	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(3.8)	(4.9)	(6.4)	(5.6)	(20.6)	(5.2)	(5.2)	(5.2)	(5.3)	(21.0)
EBITDA																				
Shares, Basic	17.5	30.0	38.9	41.0	31.8	45.7	47.8	47.8	47.8	47.3	48.0	48.0	48.1	48.2	48.1	48.3	48.4	48.5	48.6	48.4
Shares, Diluted	17.5	30.0	38.9	41.0	31.8	45.7	47.8	47.8	47.8	47.3	48.0	48.0	48.1	48.2	48.1	48.3	48.4	48.5	48.6	48.4
EPS Basic (Pro forma)	(\$0.22)	(\$0.11)	(\$0.08)	(\$0,10)	(\$0.45)	(\$0.08)	(\$0.12)	(\$0.08)	(\$0.12)	(\$0.40)	(\$0.08)	(\$0.10)	(\$0.13)	(\$0.12)	(\$0.43)	(\$0.11)	(\$0.11)	(\$0.11)	(\$0.11)	(\$0.43)
EPS Diluted (Pro forma)	(\$0.22)	(\$0.11)	(\$0.08)	(\$0.10)	(\$0.45)	(\$0.08)	(\$0.12)	(\$0.08)	(\$0.12)	(\$0.40)	(\$0.08)	(\$0.10)	(\$0.13)	(\$0.12)	(\$0.43)	(\$0.11)	(\$0.11)	(\$0.11)	(\$0.11)	(\$0.43)
Manaina																				
Margins Gross margin	-353%	-400%	-467%	-371%	-394%	-746%	-1113%	-376%	-247%	-530%	-133%	-130%	100%	-100%	-84%	-100%	-100%	-100%	-100%	-100%
Research and development	1996%	-400% 3658%	-467% 3061%	-371% 5374%	3509%	5086%	5726%	6079%	-247% 5735%	-330 % 5683%	3139%	8250%	6533%	6239%	5984%	9091%	10000%	9524%	5348%	7968%
General and administrative	5040%	4293%	5792%	6152%	5309%	7543%	9326%	5452%	5129%	6424%	6279%	7270%	24619%	3565%	8153%	6667%	7333%	6984%	3922%	58439
Operating margin	-7389%		-9319%		-9296%	-13375%		-11906%		-13954%		-15650%			#########		########		-9369%	#######
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin			-9183%	-9324%	-8834%		-25548%			-14168%		-16170%			########		########		-9369%	#######
Y/Y % change																				
Total Revenue	#DIV/0!	38%	-41%	-16%	16%	-38%	-43%	-8%	21%	-17%	18%	30%	-36%	10%	4%	0%	0%	50%	0%	79
Gross margin	-31%	-14%	-1%	-7%	-15%	31%	60%	-26%	-19%	11%	-79%	-85%	-117%	-55%	-83%	-25%	-23%	-250%	0%	289
Research and development	-3%	33%	-7%	57%	23%	59%	-10%	82%	30%	34%	-27%	88%	-32%	20%	9%	190%	21%	119%	-14%	43%
General and administrative	28%	-12%	13%	74%	23%	-7%	25%	-14%	1%	0%	-2%	2%	187%	-24%	32%	6%	1%	-57%	10%	-239
Operating income (loss)	14%	4%	5%	66%	22%	13%	11%	17%	45%	24%	-16%	26%	66%	-25%	6%	66%	11%	-20%	-5%	5%
Net income (loss)	13%	66%	12%	230%	51%	-6%	74%	16%	49%	33%	7%	-17%	67%	-5%	8%	37%	8%	-18%	-5%	29
EPS Diluted (Pro forma)	-93%	-89%	-92%	-28%	-83%	-64%	9%	-6%	28%	-11%	2%	-18%	66%	-6%	6%	36%	7%	-19%	-6%	1%
Source: Company reports and A	scendian	Canital	Markots	estimator		I					L				I	I				L



AIM ImmunoTech Inc.

Balance Sheet (\$ mils) Mar-20 Jun-20 Sep-20 Dec-20 Mar-21 Jun-21 Sep-21 Dec-21 Mar-22 Jun-22 Sep-22 Dec-22 Mar-23 Jun-23 Sep-23 Dec-23 Fiscal Year End: December 31 Q1A Q2A Q3A Q4A Q1A Q2A Q3A Q4A Q1A Q2A Q3A Q4E Q1E Q2E Q3E Q4E Assets Cash and cash equivalents 27.6 33.9 38.5 38.5 48.8 41.1 37.3 32.1 29.0 34.5 29.8 30.1 25.8 20.7 15.5 10.3 Short term investments 0.5 1 1 11 0.5 12 0.5 16.2 15.6 73 70 70 70 70 70 70 Accounts receivable, net 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Inventory 0.0 0.0 0.0 0.0 0.0 Deferred income taxes 0.0 0.0 0.0 0.0 0.0 Prepaid expenses and other 1.6 0.1 0.1 1.3 1.2 0.2 0.2 1.9 5.8 4.3 4.4 0.3 0.2 0.2 0.2 0.3 51.2 41.3 50.2 41.2 27.9 22.7 Total current assets 29.7 35.2 39.8 40.3 38.0 50.4 46.0 37.4 33.0 17.6 Long term securities/investments 3.0 5.3 14.8 15.4 13.7 16.1 15.8 0.0 0.0 0.0 0.0 0.0 Property and equipment, net 7.0 6.8 6.6 6.5 6.3 6.1 6.0 4.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Intangibles, net 1.2 1.4 1.8 2.0 3.5 2.0 2.0 2.0 2.0 2.0 1.4 1.5 1.8 1.8 2.0 2.0 Deferred income tax 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <u>0.0</u> 0.0 0.0 Other 1.5 1.5 1.5 0.9 1.1 1.3 1.4 1.5 0.1 2.7 3.0 Total assets 42.4 50.1 64.2 64.6 74.1 66.7 63.1 57.7 54.2 50.9 46.3 39.5 35.1 30.0 24.8 19.7 Liabilities and stockholders' equity Accounts payable 0.2 0.3 0.2 0.4 0.2 0.5 0.4 0.2 0.4 0.7 1.0 0.6 0.7 0.6 0.6 0.6 Accrued expenses 0.3 0.3 0.3 0.4 0.5 0.4 0.4 0.4 0.3 0.5 1.8 0.6 1.0 0.9 0.6 0.6 Accrued interest 0.0 0.0 0.0 0.0 0.0 Deferred revenue 0.0 0.0 0.0 0.0 0.0 Deferred income tax 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.3 0.3 Other 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.3 0.3 Short term debt 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 Total current liabilities 0.7 0.8 1.1 0.7 2.9 2.0 1.8 0.8 1.0 0.9 0.8 0.8 1.4 1.4 1.6 1.4 Deferred income taxes 0.0 0.0 0.0 0.0 0.0 Warrant liabilities 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Other long term liabilities 0.1 0.1 0.1 0.1 0.1 0.7 0.7 0.7 0.7 0.7 0.7 0.1 0.1 0.1 0.1 0.7 Long term debt <u>0.0</u> <u>0.0</u> 0.0 6.2 <u>2.0</u> 1.9 1.9 1.8 <u>0.0</u> <u>0.0</u> Total other liabilities 6.6 2.3 2.3 2.2 2.2 0.3 0.3 0.1 0.1 0.7 0.7 0.7 0.7 0.7 0.7 0.7 Preferred stock 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 Common stock 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.6 0.9 1.1 1.4 Additional paid-in capital 366.2 381.4 398.9 402.5 416.0 416.4 416.8 417.2 417.5 417 8 418 1 418 1 418 1 418.1 418 1 418 1 Retained earnings (331.9) (335.3)(338.6)(342.0 (345.6) (351.4)(355.3)(361.1 (364.9)(369.8)(376.2)(381.7)(386.9)(392.2)(397.4)(402.7 Treasury stock 0.0 0.0 0.0 0.0 0.0 Accumulated other comprehensive in (0.0)0.1 (0.0)(0.0 (0.2)(0.2)(0.3)0.0 0.0 0.0 0.0 0.0 Other 0.0 0.0 0.0 0.0 0.0 Total stockholders' equity 35.1 61.3 53.3 42.7 32.5 27.5 47.0 61.1 71.0 65.5 62.0 56.9 48.8 37.4 22.5 17.6 Total stockholders' equity and liabil 42.4 50.1 64.2 64.6 74.1 66.7 63.1 57.7 54.2 50.9 46.3 39.5 35.1 30.0 24.8 19.7

Balance Sheet Drivers																
	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4E	Q1E	Q2E	Q3E	Q4E
Prepaid as % of total rev	3500%	295%	253%	3033%	4457%	674%	488%	3814%	17688%	14243%	20976%	500%	500%	500%	500%	500%
Accounts payable as % of total rev	367%	638%	569%	912%	675%	1961%	1118%	388%	1145%	2373%	4557%	1000%	2000%	2000%	2000%	1000%
Inventories as % of cost of rev	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	#DIV/0!	0%	0%	0%	0%	0%
Accrued expenses as % of total rev	636%	813%	894%	1052%	1779%	1622%	1097%	859%	994%	1673%	8414%	1000%	3000%	3000%	2000%	1000%
Activity Ratios																
A/R Days Sales Outstanding	92	104	65			110	76	0	0	0	0	70	70	70	70	70
Inventory Turnover	#DIV/0!															
A/P Days Payable	73	115	90	174	72	145	212	101	442	929	#DIV/0!	450	900	900	900	450
Book & Cash Value (per share)																
Book Value per Share (diluted)	\$2.01	\$1.57	\$1.57	\$1.49	\$1.55	\$1.37	\$1.30	\$1.19	\$1.11	\$1.02	\$0.89	\$0.78	\$0.67	\$0.57	\$0.47	\$0.36
Cash per Share (diluted)	\$1.78	\$1.34	\$1.40	\$1.33	\$1.39	\$1.20	\$1.12	\$1.01	\$0.93	\$0.87	\$0.76	\$0.77	\$0.68	\$0.57	\$0.46	\$0.36
Net cash per Share (diluted)	\$1.41	\$1.27	\$1.34	\$1.27	\$1.35	\$1.20	\$1.12	\$1.01	\$0.93	\$0.87	\$0.76	\$0.77	\$0.68	\$0.57	\$0.46	\$0.36

Source: Company reports and Ascendiant Capital Markets estimates



AIM ImmunoTech Inc.

Cash Flow Statement (\$ mils)	Mar-20	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activiti	es																			
Net income	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(3.8)	(4.9)	(6.4)	(5.6)	(20.6)	(5.2)	(5.2)	(5.2)	(5.3)	(21.0
Depreciation	0.2	0.2	0.2	0.2	0.7	0.2	0.2	0.2	0.2	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortization	0.2	(0.1)	(0.0)	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0		0.1					0.0
Debt related amortization expen	0.2	(0.1)	0.0	0.0	0.1	0.0	0.0			0.0					0.0					0.0
Stock comp	0.2	0.1	0.3	0.4	1.0	0.5	0.5	0.3	0.2	1.6	0.2	0.3	0.3	0.3	1.1	0.3	0.3	0.3	0.3	1.1
Deferred income taxes					0.0	(0.2)	0.2	(0.5)	0.5	0.0				0.0	0.0	0.0	0.0	0.0	0.0	0.0
Provision for bad debts				(0.0)	(0.0)					0.0					0.0					0.0
Reserves					0.0					0.0					0.0					0.0
Change in fair value of warrant I	0.2	(0.0)	(0.0)	(0.0)	0.1	0.0	(0.0)	(0.1)	(0.1)	(0.1)	(0.0)	(0.0)	(0.7)		(0.8)					0.0
Writedowns and impairments				1.4	1.4				1.8	1.8					0.0					0.0
Other gains/losses	(0.0)	0.2	(0.1)	(0.1)	0.0		2.0	0.6	(2.4)	0.2	0.7	(0.5)	1.5		1.8					0.0
Other		0.0	(0.1)	0.0	0.0	0.0	0.0	0.0	(0.0)	0.0	0.0	(0.0)	(0.7)		(0.7)					0.0
Changes in operating assets and lia	abilities:																			1
Accounts receivable	(0.0)	0.8	0.0	(0.8)	0.0		0.0		0.0	0.0				(0.0)	(0.0)	0.0	0.0	(0.0)	(0.0)	0.0
Inventory				· · · · ·	0.0					0.0				0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses & other curre	0.0	0.7	0.1	(0.1)	0.7	0.0	0.0	(0.0)	1.6	1.6	0.0	1.6	(2.1)	4.1	3.6	0.1	0.0	(0.0)	(0.1)	0.0
Income tax				(0.3)	(0.3)		1.1		(1.1)	0.0					0.0					0.0
Other assets	(0.0)	(0.0)	(0.2)	0.3	0.0	(0.0)	(0.0)	(0.0)	(0.5)	(0.6)	(0.0)	0.7	1.6	3.0	5.3	0.0	0.0	0.0	0.0	0.0
Accounts payable	(0.3)	0.1	0.4	(0.3)	(0.1)	(0.2)	0.3	(0.1)	(0.2)	(0.2)	0.2	0.3	0.2	(0.4)	0.4	0.1	(0.1)	0.0	(0.1)	0.0
Accrued expenses	(0.1)	0.0	(0.2)	0.4	0.0	0.1	(0.1)	(0.0)	0.1	(0.0)	(0.1)	0.2	1.3	(1.2)	0.1	0.4	(0.1)	(0.3)	(0.1)	0.0
Accrued interest	0.1	0.1	()	0.0	0.2		()	()		0.0	()			0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenue					0.0					0.0				0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities					0.0					0.0				0.1	0.1	0.0	0.0	0.0	0.0	0.0
Net cash (used in) provided by	(3.1)	(1.5)	(3.0)	(2.9)	(10.4)	(3.0)	(1.7)	(3.5)	(5.7)	(14.0)	(2.8)	(2.3)	(5.0)	0.3	(9.7)	(4.3)	(5.1)	(5.2)	(5.3)	(19.8
Cook flow from investing ontiviti																				
Cash flow from investing activitie		(0.0)	(0, 0)	(0.0)	(0.0)			(0.0)	(0,0)											
Purchases of property and equi	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)		0.2	(0.0)	(0.0)	0.2	(0.0)		(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchases of short-term investm	3.8	(2.9)	(9.6)	0.1	(8.6)	0.9	(1.4)	(0.3)	0.5	(0.2)	(0.3)	7.8	(0.0)		7.4					0.0
Acquisitions	(0.3)			(0.3)	(0.6)	(0.4)		(0.1)	(0.1)	(0.6)	(0.0)	(0.0)	0.3		0.2					0.0
Other					<u>0.0</u>					<u>0.0</u>					<u>0.0</u>					0.0
Net cash used in investing activ	3.5	(2.9)	(9.6)	(0.2)	(9.2)	0.5	(1.2)	(0.4)	0.4	(0.6)	(0.3)	7.7	0.3	0.0	7.6	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activiti	es																			
Issuance of debt				(0.4)	(0.4)					0.0				0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of debt	(0.1)	(4.4)	(0.1)	0.2	(4.3)	(0.1)	(4.8)	(0.0)	0.0	(4.9)					0.0					0.0
Issuance of stock	25.8	15.0	17.2	3.2	61.2	12.9		0.0	0.1	13.0		0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Repurchase of common stock					0.0					0.0					0.0					0.0
Proceeds from stock option exer	cises				0.0					0.0					0.0					0.0
Other					0.0					0.0					0.0					0.0
Dividends and distributions					0.0					0.0					0.0					0.0
Cash provided by (used in) fina	25.7	10.7	17.2	3.0	56.6	12.8	(4.8)	0.0	0.1	8.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Effect of exchange rate on cash					0.0					0.0					0.0					0.0
Not increase (decrease) in each	26.1	6.3	4.6	0.0	37.0	10.2	(7.6)	(3.9)	(5.2)	(6.4)	(2.4)	5 F	(4.7)	0.2	(2.0)	(4.2)	(5.4)	(5.2)	(5.2)	(19.8
Net increase (decrease) in cash	26.1 1.5					10.3	(7.6)	(3.8)	(5.3)	(6.4)	(3.1)	5.5	(4.7)	0.3	(2.0)	(4.3)	(5.1)	(5.2)	(5.3)	
Beginning cash and equivalents		27.6	33.9	38.5	1.5	38.5	48.8	41.1	37.3	38.5	32.1	29.0	34.5	29.8	32.1	30.1	25.8	20.7	15.5	30.1
Ending cash and equivalents	27.6	33.9	38.5	38.5	38.5	48.8	41.1	37.3	32.1	32.1	29.0	34.5	29.8	30.1	30.1	25.8	20.7	15.5	10.3	10.3


Source: Company reports and Ascendiant Capital Markets estimates



ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

AIM ImmunoTech Inc.



Source: https://bigcharts.marketwatch.com/

	Report Date		Price
Report	Date	Rating	Target
1	10/29/2018	Buy	33.00
2	11/21/2018	Buy	30.80
3	4/2/2019	Buy	28.60
4	5/16/2019	Buy	26.40
5	8/21/2019	Buy	6.00
6	11/17/2019	Buy	2.50
7	1/26/2020	Buy	3.00
8	4/4/2020	Buy	6.00
9	5/24/2020	Buy	7.00
10	8/21/2020	Buy	7.25
11	11/28/2020	Buy	7.50
12	4/6/2021	Buy	7.75
13	5/21/2021	Buy	8.00
14	9/7/2021	Buy	8.50
15	11/28/2021	Buy	8.75
16	4/12/2022	Buy	8.00
17	6/4/2022	Buy	7.50
18	9/11/2022	Buy	7.25

• Ascendiant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as



appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendiant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendiant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech stocks, and changes in consumer or government priorities for healthcare.

Ascendiant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

- HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.
- SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Rating System

Prior to January 31, 2014, ASCM used the following rating system:

Strong Buy:	We expect the stock to provide a total return of 30% or more within a 12-month period.
-------------	--

- **Buy:** We expect the stock to provide a total return of between 10% and 30% within a 12-month period.
- Neutral: We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.
- Sell: We expect the stock to provide a total return of minus 10% or worse within a 12-month period.
- **Speculative Buy:** This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below \$50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.



Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	43	98%	17	40%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	44	100%	17	39%

Ascendiant Capital Markets, LLC Distribution of Investment Ratings (as of October 7, 2022)

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.